Robeco Institutional Asset Management B.V. Buys New Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Robeco Institutional Asset Management initiated a new Kiniksa Pharmaceuticals stake of 14,025 shares valued at approximately $1.05 million. Institutional investors collectively own 53.95% of KNSA.
• Kiniksa reported quarterly revenue of $243.6 million and adjusted earnings of $0.30 per share, meeting EPS expectations while exceeding revenue estimates. Shares opened at $72.98, compared with a 52-week range of $35.20 to $84.06.
• Analysts remain broadly positive, with eight Buy ratings and one Hold; the consensus rating is Moderate Buy with a $93.14 target price. Recent targets range from $87 to $107, though company insiders have sold shares.

Robeco Institutional Asset Management B.V. bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 14,025 shares of the company's stock, valued at approximately $1,046,000.

Other large investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $1,161,000. Inspire Investing LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth $1,698,000. OMERS ADMINISTRATION Corp bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $631,000. Handelsbanken Fonder AB bought a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth $1,343,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Kiniksa Pharmaceuticals International by 56.7% during the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company's stock worth $3,050,000 after acquiring an additional 22,917 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $72.98 on Tuesday. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of 75.24 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1 year low of $35.20 and a 1 year high of $84.06. The business's 50 day simple moving average is $78.03 and its 200-day simple moving average is $59.00.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. The firm had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on KNSA shares. Wells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, September 30th. They set an "overweight" rating and a $87.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Finally, Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $93.14.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael Megna sold 4,600 shares of the company's stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer owned 29,062 shares of the company's stock, valued at $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the company's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director directly owned 11,672 shares in the company, valued at approximately $950,450.96. The trade was a 23.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 51.98% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.